Trials / Completed
CompletedNCT05307406
A First-in-Human Study With XAB05 in Healthy Subjects
A First-in-Human Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Exploratory Markers of Efficacy for XAB05 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Xenothera SAS · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study is a randomized, placebo-controlled, first in human, single ascending dose Phase 1 study
Detailed description
This study is a First in Human (FIH) single ascending dose study with XAB05 to evaluate safety, tolerability, PK and exploratory markers of efficacy for XAB05 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Experimental | Participants will receive a single IV infusion in a double blind manner |
Timeline
- Start date
- 2022-01-24
- Primary completion
- 2022-05-19
- Completion
- 2022-05-19
- First posted
- 2022-04-01
- Last updated
- 2022-08-12
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05307406. Inclusion in this directory is not an endorsement.